AI assistant
Sending…
IO Biotech, Inc. — Director's Dealing 2021
Nov 12, 2021
34883_dirs_2021-11-12_bf8fb5e6-8186-4bc5-8f3d-7dc7ade6431d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2021-11-09
Reporting Person: HBM Healthcare Investments (Cayman) Ltd. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-09 | Common Stock | C | 2365545 | — | Acquired | 2365545 | Direct |
| 2021-11-09 | Common Stock | P | 325000 | $14 | Acquired | 2690545 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-09 | Series C Preferred Stock | $ | C | 188168 | Disposed | Common Stock (2365545) | Direct |
Footnotes
F1: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
More from IO Biotech, Inc.
Board/Management Information
2026
Mar 31
Delisting Announcement
2026
Feb 13
Major Shareholding Notification
2026
Feb 13
Major Shareholding Notification
2026
Feb 6
Regulatory Filings
2026
Jan 30
Major Shareholding Notification
2026
Jan 23
Regulatory Filings
2026
Jan 21
Delisting Announcement
2025
Dec 19
Board/Management Information
2025
Nov 21
Investor Presentation
2025
Nov 18